Cancer vaccines in phase II/III clinical trials: State of the art and future perspectives

S. Cecco, E. Muraro, E. Giacomin, D. Martorelli, R. Lazzarini, P. Baldo, R. Dolcetti

Research output: Contribution to journalArticlepeer-review

Abstract

The topic of this review covers a very important branch of cancer research, cancer vaccination. The growing knowledge in tumor immunology has evolved rapidly, starting from unspecific generic stimulation of the immune system to more specific approaches based on the availability of tumor antigens. The review covers molecular and cell biology, and pharmaceutical technology of cancer vaccines. Particularly, it is aimed at highlighting the results of cancer vaccines from phase II and III clinical trials, an issue that is of relevance to better understand how cancer vaccines can successfully complement antitumor therapy, including conventional chemotherapy and the recently developed target-based drugs.

Original languageEnglish
Pages (from-to)85-102
Number of pages18
JournalCurrent Cancer Drug Targets
Volume11
Issue number1
DOIs
Publication statusPublished - 2011

Keywords

  • Cancer
  • Clinical trials
  • Immunotherapy
  • Investigational drugs
  • Therapeutic vaccines
  • Tumor-associated antigen

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Cancer vaccines in phase II/III clinical trials: State of the art and future perspectives'. Together they form a unique fingerprint.

Cite this